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Objectives: To assess risk factors for fluoroquinolone resistance in community-onset febrile Escherichia coli
urinary tract infection (UTI).
Methods: A nested case–control study within a cohort of consecutive adults with febrile UTI presenting
at primary healthcare centres or emergency departments during January 2004 through December 2009.
Resistance was defined using EUCAST criteria (ciprofloxacin MIC .1.0 mg/L). Cases were subjects with
fluoroquinolone-resistant E. coli, and controls those with fluoroquinolone-susceptible isolates. Multivariable
logistic regression analysis was used to identify potential risk factors for fluoroquinolone resistance.
Results: Of 787 consecutive patients, 420 had E. coli-positive urine cultures. Of these, 51 (12%) were fluoroqui-
nolone resistant. Independent risk factors for fluoroquinolone resistance were urinary catheter [odds ratio (OR)
3.1; 95% confidence interval (CI) 0.9–11.6], recent hospitalization (OR 2.0; 95% CI 1.0–4.3) and fluoroquino-
lone use in the past 6 months (OR 17.5; 95% CI 6.0–50.7). Environmental factors (e.g. contact with
animals or hospitalized household members) were not associated with fluoroquinolone resistance. Of fluoro-
quinolone-resistant strains, 33% were resistant to amoxicillin/clavulanate and 65% to trimethoprim/
sulfamethoxazole; 14% were extended-spectrum b-lactamase (ESBL) positive compared with ,1% of
fluoroquinolone-susceptible isolates.
Conclusions: Recent hospitalization, urinary catheter and fluoroquinolone use in the past 6 months were inde-
pendent risk factors for fluoroquinolone resistance in community-onset febrile E. coli UTI. Contact with animals
or hospitalized household members was not associated with fluoroquinolone resistance. Fluoroquinolone
resistance may be a marker of broader resistance, including ESBL positivity.
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Introduction
Fluoroquinolones and trimethoprim/sulfamethoxazole are the
preferred agents for oral treatment of febrile urinary tract
infection (UTI). Fluoroquinolones are recommended to be the
first choice, particularly, because there is a relatively low
rate of antimicrobial resistance.1 – 4 However, the emergence of
fluoroquinolone-resistant Escherichia coli in the community
may limit oral treatment options.5 Reported rates of E. coli
resistance to ciprofloxacin in UTI vary widely over the years
and between countries, ranging from ,1% to 38%.6,7 In the
Netherlands, a country known for its restrictive usage of antimi-
crobials and overall low rates of antimicrobial resistance, E. coli
resistance to ciprofloxacin increased from 3% in 2001 to 11%
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in 2008 with even higher rates in patients at urology services.8,9
Moreover, fluoroquinolone resistance in E. coli isolates is fre-
quently associated with resistance to other classes of anti-
biotics.10 Therefore, there is a need for knowledge of risk
factors for fluoroquinolone-resistant E. coli in patients presenting
with febrile UTI in order to select the most appropriate empirical
antimicrobial oral treatment.
Previous studies on fluoroquinolone-resistant E. coli have
focused primarily on host-related risk factors such as older
age, prior fluoroquinolone usage, urinary tract disorders and
hospitalization.7,11 – 16 Others have studied the emergence of
E. coli resistance in the environment and found household
members, pets and livestock colonized with resistant E. coli
strains to be possible sources of human infection.17 – 20 To our
knowledge, these potential environmental risk factors for
fluoroquinolone resistance have not been assessed in a general
population presenting with community-onset febrile UTI or
acute pyelonephritis.
We therefore conducted a multicentre nested case–control
study to identify host-related and environmental risk factors
for fluoroquinolone resistance in adults presenting with
community-onset febrile UTI. In addition, the relationship with
extended-spectrum b-lactamase (ESBL) positivity was
investigated.
Patients and methods
We conducted a nested case–control study from a prospective multicen-
tre cohort study. Participating centres were 35 primary healthcare
centres and emergency departments of 7 hospitals, all clustered in one
area of the Netherlands. From January 2004 until December 2009, con-
secutive patients who presented with febrile UTI were considered for
enrolment in the study. The local ethics committees approved the
study and all participants provided written informed consent.
Inclusion criteria were age ≥18 years, fever (≥38.08C) and/or a history
of fever and chills within 24 h before presentation, at least one symptom
of UTI (dysuria, frequency, urgency, perineal pain, flank pain or costover-
tebral tenderness) and a positive nitrite dipstick test or leucocyturia as
defined by a positive leucocyte esterase dipstick test or the presence of
more than five leucocytes per high-power field (pyuria) in a centrifuged
sediment. Exclusion criteria were current treatment for urolithiasis or
hydronephrosis, pregnancy, haemo- or peritoneal dialysis, a history of
kidney transplantation or known presence of polycystic kidney disease.
Patients were only included once in the study.
Cases were eligible patients with urine culture-confirmed febrile UTI
caused by fluoroquinolone-resistant E. coli. Patients with febrile UTI due
to fluoroquinolone-susceptible E. coli served as controls.
Procedures
Demographic, clinical and microbiological data were collected within
24–48 h of notification. This was done by qualified research nurses or
the clinical investigators (C. v. N. and W. E. v. d. S.) by reviewing the
medical record completed with an interview by telephone or in person
using a standardized questionnaire including host-related variables. All
patients were empirically treated with antibiotics according to local
policy (500 mg of oral ciprofloxacin twice daily for outpatients and for
inpatients cefuroxime+gentamicin intravenously). Based on the culture
results, hospitalized patients were subsequently switched to oral anti-
biotic treatment (first choice 500 mg of ciprofloxacin twice daily).
As data on environmental exposure were initially not collected, we
contacted patients for a second time in March 2010. All cases were
selected for additional interview and for each case, two controls were
selected matched by centre and date of inclusion. A standardized ques-
tionnaire was used containing the following dichotomous items present
within 3 months before initial inclusion: household member with UTI;
recent hospitalization; working in healthcare facility; ownership and/or
contact with pets or livestock; and receipt of home healthcare support.
The interviewer was blinded to the antimicrobial susceptibility outcome
of the isolated E. coli strains.
Definitions
Recurrent UTI was defined as two or more episodes in the last 6 months
or three or more episodes of UTI in the last year. A urinary tract disorder
was defined as the presence of any functional or anatomical abnormality
of the urinary tract excluding the presence of a urinary catheter or history
of nephrolithiasis. These two latter variables were analysed separately.
Data regarding recurrent UTI and antibiotic use in the past 6 months
were missing in 5 and 13 patients, respectively. Missing values of these
categorical variables were considered to indicate the absence of that
characteristic.
Microbiological analysis
Clean midstream-catch urine cultures were obtained before starting anti-
microbial therapy and were analysed using local standard microbiological
methods. In the case of a urinary catheter the urine sample was col-
lected from the port of the catheter. A positive urine culture was
defined as bacterial growth of .103 cfu/mL urine or a bacterial monocul-
ture of .102 cfu/mL urine in the presence of pyuria.21 Urine cultures
revealing growth of two or more different bacterial species reflecting
mixed skin or gut flora, were considered to indicate contamination.21
Susceptibility tests were done from the selective media using the
Vitek2 system (bioMerieux). MIC breakpoints for resistance were based
on EUCAST criteria (www.eucast.org). E. coli isolates for which ciprofloxa-
cin MICs were .1 mg/L were considered to be fluoroquinolone
resistant. In 16 E. coli isolates ciprofloxacin susceptibility was not
specifically tested. Fifteen of these were norfloxacin susceptible and
thus considered fluoroquinolone susceptible; one was resistant to
norfloxacin and considered fluoroquinolone resistant.
ESBL production was phenotypically detected by double-disc diffusion
test using ceftazidime/ceftazidime clavulanate and cefotaxime/cefotaxime
clavulanate or by Etest.
Statistical analysis
Descriptive analysis included means or percentages with 95% confidence
intervals (CIs) or medians and ranges, as appropriate. Univariate analysis
was performed using the Mann–Whitney U-test for continuous variables
and x2 tests for categorical variables. All variables associated with cipro-
floxacin resistance in univariate analysis with P,0.2 were included in a
multiple logistic regression model using a backward selection method
with conditional tests. Interactions between paired variables were
tested. A two-tailed P value of ,0.05 was considered to indicate statisti-
cal significance. All analysis was performed using SPSS 17.0 (SPSS Inc.,
Chicago, IL, USA).
Results
During the study period, 787 patients with febrile UTI were
enrolled. E. coli was the most frequent causal uropathogen,
present in 420 (53%) of the patients. Additional causative organ-
isms were Klebsiella spp. (4.1%), Enterococcus faecalis (1.6%)
and others (Figure 1). In 199 (25%) patients, urine culture












showed either no significant bacteriuria or mixed flora; 52% of
them could be explained by antibiotic pre-treatment.
Of 420 patients with E. coli-positive urine cultures, 51 (12%)
had a culture with a fluoroquinolone-resistant isolate (desig-
nated as cases) and 369 with a fluoroquinolone-susceptible
isolate (designated as controls). The median age was 66 years
[interquartile range (IQR) 45–78], 137 (33%) were men and
224 (53%) had co-morbidity. Baseline characteristics of the
study population are summarized in Table 1.
Out of the 369 controls, 102 were matched by centre and
date of inclusion to the 51 cases for additional interview on
environmental issues, but otherwise selected randomly. These
102 selected controls were comparable to the remaining 267
controls with respect to gender, age and comorbidity, except
for diabetes mellitus, which was more frequent in the selected
controls (19% versus 11%, P¼0.047). During follow-up till
March 2010, 9 cases and 11 controls died. Of the remaining
42 cases and 93 controls, 38 cases (response rate 90%) and
74 controls (response rate 80%) participated (Figure 1).
Risk factors for fluoroquinolone-resistant E. coli
Univariate and multivariate potential risk factors for
fluoroquinolone-resistant E. coli are listed in Table 1. Significant
univariable host-related risk factors were the presence of a
urinary catheter [odds ratio (OR) 6.0; 95% confidence interval
(CI) 2.0–18.1], underlying urinary tract disorder (OR 2.3; 95%
CI 1.2–4.4), recurrent UTI (OR 2.2; 95% CI 1.2–4.1), hospitaliz-
ation in the past 6 months (OR 2.3; 95% CI 1.2–4.4) and
fluoroquinolone usage in the past 6 months (OR 18.6; 95%
CI 6.6–52.4). None of the environmental characteristics was
significantly associated with fluoroquinolone resistance, with
ORs all 1.
787 Consecutive adults with
febrile UTI
  January 2004–December 2009 
420 Patients with febrile
E. coli  UTI    
 367 Urine culture result other than E. coli 
   n (%)
E. faecalis 13 (2) 
Klebsiella spp. 32 (4) 
Proteus spp. 18 (2) 
Pseudomonas aeruginosa 18 (2) 
Staphylococcus aureus   6 (1) 
Staphylococcus saprophyticus 9 (1) 
Enterobacter spp.   4 (1) 
other 23 (3) 
none or contaminated 199 (25) 
no culture performed 45 (6) 
51 FQ-resistant E. coli
Cases  
369 FQ-susceptible E. coli
Controls  
11 died 
17 lost to follow-up 
9 died 
3 lost to follow-up 
1 refused participation
102 Controls selected for
questionnaire on patient’s
environment
March 2010   
51 Cases selected for
questionnaire on patient’s
environment
March 2010    
38 Cases with completed
questionnaire
   




A, analysis of host-related risk factors for FQ resistance. 
B, analysis of environmental risk factors for FQ resistance. 
Figure 1. Flow chart of participants in the study. FQ, fluoroquinolone.











Independent risk factors for fluoroquinolone-resistant E. coli
in the multivariate analysis were the presence of a urinary
catheter (OR 3.1; 95% CI 0.9–11.6), recent hospitalization
(OR 2.0; 95% CI 1.0–4.3) and fluoroquinolone use in the
past 6 months (OR 17.5; 95% CI 6.0–50.7). Potential
interactions between variables (e.g. urinary tract disorder and
presence of a urinary catheter), were additionally tested, but
they did not significantly change the model. In total, 90
(21%) of the patients had at least one of those three risk
factors accompanied by a 26.7% risk of having
fluoroquinolone-resistant E. coli compared with 330 patients
with no risk factor who had an 8.2% risk of having
fluoroquinolone-resistant E. coli.
Microbiological outcome
Among 420 E. coli isolates tested, 12% were resistant to cipro-
floxacin, 51% to amoxicillin, 11% to amoxicillin/clavulanate,
30% to trimethoprim/sulfamethoxazole, 5% to cefuroxime and
6% to gentamicin. Fluoroquinolone-resistant E. coli strains were
frequently resistant to other antibiotic classes used for treatment
of febrile UTI: 33% to amoxicillin/clavulanate; and 65% to
trimethoprim/sulfamethoxazole. The distribution of cross-
resistance to oral antibiotics used for febrile UTI is illustrated in
Figure 2. The prevalence of ESBL-producing E. coli was low
(2%), but differed significantly between cases and controls
[7 (14%) versus 1 (,1%), respectively (P,0.001)]. Of the eight
patients with ESBL-positive E. coli, six completed the
Table 1. Baseline characteristics of 420 patients presenting with febrile UTI due to E. coli









Age, years, median (IQR) 66 (45–78) 71 (54–80) 66 (44–78) 0.115
≥65 years 216 (51) 30 (59) 186 (50) 1.41 (0.78–2.54) 0.260
Male sex 137 (33) 18 (35) 119 (32) 1.15 (0.62–2.12) 0.664
Co-morbidity
any 224 (53) 33 (65) 191 (52) 1.71 (0.93–3.14) 0.082
urinary catheter 14 (3) 6 (12) 8 (2) 6.02 (2.00–18.1) ,0.001 3.14 (0.85–11.60)
urinary tract disorderb 83 (20) 17 (33) 66 (18) 2.30 (1.21–4.35) 0.009
history of nephrolithiasis 38 (9) 5 (10) 33 (9) 1.11 (0.41–2.98) 0.841
diabetes mellitus 59 (14) 11 (22) 48 (13) 1.84 (0.88–3.83) 0.099
malignancy 34 (8) 6 (12) 28 (8) 1.62 (0.64–4.14) 0.305
cerebrovascular disease 57 (14) 7 (14) 50 (14) 1.02 (0.43–2.38) 0.973
COPD 52 (12) 7 (14) 45 (12) 1.15 (0.49–2.70) 0.756
immunocompromised state 44 (11) 4 (8) 40 (11) 0.70 (0.24–2.05) 0.512
Recurrent UTIc 109 (26) 21 (41) 88 (24) 2.24 (1.22–4.10) 0.008
Hospitalization in the past 6 months 72 (17) 15 (29) 57 (15) 2.28 (1.17–4.44) 0.013 2.03 (0.96–4.31)
Residence in nursing home 16 (4) 4 (8) 12 (3) 2.53 (0.78–8.17) 0.108
Antibiotic treatment in the past 6 months 140/407 (34) 23/49 (47) 117/358 (33) 1.82 (1.00–3.33) 0.049
fluoroquinolones 18 (4) 12 (24) 6 (2) 18.6 (6.62–52.4) ,0.001 17.5 (6.0–50.7)
b-lactams 30 (7) 4 (8) 26 (7) 1.12 (0.38–3.36) 0.836
trimethoprim/sulphonamide 14 (3) 2 (4) 12 (3) 1.21 (0.26–5.59) 0.803
nitrofurantoin 16 (4) 2 (4) 14 (4) 1.04 (0.23–4.70) 0.964
Patient environment characteristicsd n¼112 n¼38 n¼74
household member with UTI 3 (3) 0 3 (4) — 0.214
daily contact with petse 28 (25) 10 (26) 18(24) 1.12 (0.45–2.72) 0.818
daily contact with livestock 1 (1) 1 (3) 0 (0) — 0.161
household healthcare employee 9 (8) 3 (8) 6 (8) 0.97 (0.23–4.12) 0.969
home care medical support 19 (17) 7 (18) 12 (16) 1.17 (0.42–3.26) 0.768
Data are presented as n (%), unless otherwise stated. COPD, chronic obstructive pulmonary disease.
aMultivariate OR, adjusted for sex, obtained by backward regression analysis using conditional tests and selecting all variables with P,0.2 in univariate
analysis as independent covariates.
bDefined as the presence of any functional or anatomical abnormality of the urinary tract except urinary catheter and history of nephrolithiasis.
cDefined as three or more UTIs in the past 12 months or two or more UTIs in the past 6 months.
dEnvironmental characteristics evaluated in 112 patients completing questionnaire, see Figure 1.
eDogs and/or cats.












questionnaire; none of them had contact with animals. There
were no statistically significant differences in the frequency of
fluoroquinolone-resistant E. coli in the years between 2004 and
2009 and there was no trend towards a gradual increase (data
not shown).
Clinical outcome
Among the 51 patients with fluoroquinolone-resistant E. coli
febrile UTI, 16 (31%) were empirically treated with an inappropri-
ate antibiotic, including 10 patients who were treated with cipro-
floxacin (Table 2). Median fever duration in patients receiving
ciprofloxacin was 2 days (IQR 1–4); 70% of those switched to
another antibiotic after a median of 6 days (IQR 2–7). Patients
treated with cefuroxime plus gentamicin had slightly longer
fever duration [median 3 days (IQR 2–4)] and 71% switched to
another antibiotic after a median of 6.5 days (IQR 5.3–8.0)
(Table 2).
Discussion
In this study, we evaluated host-related and environmental risk
factors for fluoroquinolone resistance in adults with
community-onset febrile E. coli UTI. We identified recent hospi-
talization, the presence of a urinary catheter and fluoroquinolone
usage in the past 6 months as independent host-related risk
factors for resistance. Environmental dynamics, like contact
with pets, livestock or hospitalized household members, were
not identified as risk factors. To our knowledge, this is the first
prospective study evaluating a combination of those risk
factors for fluoroquinolone-resistant E. coli among adults with
community-onset febrile UTI or acute pyelonephritis. These
data suggest that development of fluoroquinolone resistance in
a general population at risk of febrile UTI is driven by individual
fluoroquinolone usage rather than by within-household
or animal–human transmission of resistant E. coli. However,
this study does not exclude the suggested possibility of an
animal origin of fluoroquinolone resistance via foodborne
transmission.22,23
The strengths of this study are its prospective design and the
broad population of interest, reflecting daily practice of patients
presenting with febrile UTI or acute pyelonephritis, as both
primary healthcare centres and emergency departments
participated.
There are, however, also some limitations. Our study had a
relatively small sample size of cases with fluoroquinolone resist-
ance. However, to our knowledge this study is the largest pro-
spective study on patients with fluoroquinolone-resistant E. coli
febrile UTI so far, as most previous studies were retrospective
chart reviews of microbiology laboratory databases.7,11 – 16 Such
studies may overestimate the prevalence of resistance among
uropathogens from patients with community-onset UTIs. One
study at US emergency departments had a similar prospective
design including 1271 patients with acute pyelonephritis of
which 689 were caused by E. coli.4 Yet the prevalence of
fluoroquinolone-resistant E. coli in this study was 3%–5% and
too low to evaluate risk factors for fluoroquinolone resistance.
In our study the prevalence of fluoroquinolone resistance in
E. coli was remarkably higher (12%), but consistent with a
recent survey in the Netherlands.8
We used an MIC breakpoint for ciprofloxacin resistance of
.1 mg/L according to EUCAST criteria. As, to date, different lab-
oratories over the world use different clinical MIC breakpoints for
resistance, it is of interest that we found no differences in
outcome of the patients with fluoroquinolone-resistant E. coli
who were empirically treated with ciprofloxacin compared with
those treated with appropriate antibiotics (Table 2). Moreover,
the majority of patients recovered on ciprofloxacin as their
fever resolved before the outcome of the urine culture became
available and antibiotic treatment was subsequently switched.
This may indicate that febrile UTI is to some extent a self-limiting
disease or possibly ciprofloxacin treatment may still be effective
in ranges of MICs .1 mg/L. We could not explore this hypothesis
further as we do not have results of the actual MICs for the
fluoroquinolone-resistant isolates.
Several studies also found recent hospitalization,14,15 urinary
catheter11,13 and fluoroquinolone usage7,11 – 16 to be related to
fluoroquinolone resistance. In addition, other risk factors were
discovered, such as previous invasive procedures,14 recurrent
FQs (n = 51, 12%) 
SXT (n = 126, 30%)
AMC (n = 49, 12%) 
No resistance (n = 256, 61%) 
n = 81 
n = 22 
n = 12 
n = 11 
n = 6 
n = 12 
n = 20 
n = 256 
Figure 2. Distribution of resistance to oral antibiotics in 420 patients with febrile E. coli UTI. SXT, trimethoprim/sulfamethoxazole;
FQs, fluoroquinolones; AMC, amoxicillin/clavulanate.











UTI,12,14,15 older age,7,11 presence of complicated UTI,7 under-
lying chronic disease15,16 and urinary tract abnormalities.11,15
All these risk factors for fluoroquinolone resistance seem biologi-
cally plausible and the differences in outcome of these studies
probably reflect differences in study population. However, it
should be noted that like our study, a recent meta-analysis
demonstrated that in a general population individual antibiotic
usage is the driving force for resistance of urinary bacteria.24
Though some studies identified foreign travel to be a risk factor
for infections with an antimicrobial-resistant uropathogen, in
particular a trimethoprim/sulfamethoxazole-resistant strain,
this was not found for infections with fluoroquinolone-resistant
E. coli.25 – 28 We did not systematically collect data on foreign
travel to explore this issue in our study.
Compared with previous studies we used an additional ques-
tionnaire to evaluate potential environmental risk factors for fluor-
oquinolone resistance. This was done retrospectively, holding a risk
of observer recall and selection bias. Yet several measures were
taken to minimize this. First of all, the interviewer was blinded to
the data with respect to fluoroquinolone susceptibility making
observer bias unlikely. Secondly, when obtaining the questionnaire
the patients were not specifically informed whether they had
fluoroquinolone-resistant E. coli. Furthermore, cases and controls
had comparable response rates. Thus recall bias is unlikely.
Finally, the selected controls were comparable to the non-selected
as they were randomly selected and matched only by centre and
date of presentation with febrile UTI.
We did not find environmental risk factors for fluoroquinolone
resistance. Thus our findings do not support the concern for an
animal or human reservoir of fluoroquinolone resistance. This
may contrast with previous findings, but it should be empha-
sized that the evidence for animal–human and human–
human transmission of fluoroquinolone-resistant E. coli in UTI
is limited to specific strains.17,18,20,29 As each strain could have
its specific mode and likelihood of transmission, our data do
not contradict these studies. At least it suggests that to date
such clones have not played a major role in a general Dutch
community setting of patients at risk for febrile UTI. Further sur-
veillance studies should include the genetic characterization of
E. coli strains to confirm or refute the hypothesis that fluoroqui-
nolone resistance in the community is driven by the introduction
of clonal E. coli groups.30 Furthermore, it must be emphasized
that our study does not exclude a possible two-hit mechanism
for fluoroquinolone resistance, with an initial input of
fluoroquinolone-resistant strains from food supply of colonized
animals into the population followed by selection at the individ-
ual level by personal fluoroquinolone use. Further studies are
urgently warranted to explore this hypothesis, particularly as
the relationship between animal food supply and
fluoroquinolone-resistant E. coli in humans revealed conflicting
results, but at least indicate that this might be a major
concern for the community.23,28,31,32
In cases of isolation of fluoroquinolone-resistant E. coli, we
found accompanying high rates of resistance to other antibiotics:
33% to amoxicillin/clavulanate; and 65% to trimethoprim/
sulfamethoxazole. Similar multidrug resistance rates were found
in a large study in North America.10 Moreover, 14% of
fluoroquinolone-resistant E. coli isolates in our study were ESBL
positive compared with ,1% of fluoroquinolone-susceptible iso-
lates. This supports a previous finding that fluoroquinolone sus-
ceptibility in E. coli makes the presence of ESBL positivity
unlikely.33 In this respect, this highlights the importance of risk
factors for fluoroquinolone resistance as these may also be risk
factors for ESBL production.
The extent to which antibiotic resistance risk stratification
could guide empirical therapy for febrile UTI is unknown. This
study demonstrates that the absolute risk of fluoroquinolone
resistance increases by 20% in patients with at least one of
the three risk factors we identified, but even with no risk factor
there was an 8% risk of fluoroquinolone resistance. Further
studies are therefore required in order to better stratify fluoroqui-
nolone resistance risk in patients with febrile UTI.
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Table 2. Empirical antimicrobial treatment and outcome of 51 patients with febrile UTI due to fluoroquinolone-resistant E. coli
Treatment Outcome
empirical antibiotic(s) n inappropriatea, n (%) fever duration
no. of patients switched
to other antibiotic (%) days until antibiotic switch
ciprofloxacin 10 10 (100) 2.0 (1.0–4.0) 7 (70) 6.0 (2.0–7.0)
cefuroxime 19 3 (16) 2.0 (1.0–4.0) 17 (90) 5.0 (4.0–6.0)
cefuroxime+gentamicin 14 1 (7) 3.0 (2.0–4.0) 10 (71) 6.5 (5.3–8.0)
amoxicillin/clavulanate 5 2 (40) 2.5 (1.3–3.8) 3 (60) 3.0 (3.0–3.5)
otherb 3 NA NA NA NA
NA, not applicable.
Data are presented as median (IQR), unless otherwise stated.
aInappropriate empirical antibiotic treatment defined as E. coli resistant to the antibiotic given.
bTrimethoprim/sulfamethoxazole, n¼1; ceftazidime, n¼1; and meropenem, n¼1.
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